Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status  Phase of research How it helps Latest publication
PF-00835231
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/26/2022
rLVS ΔcapB/SCoV2 MN
Potential treatment - pre-clinical evidence Experimental Vaccine Mar/30/2021
COV2-2489
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/16/2021
Nb11‐59
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/04/2021
COV2-2676
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/16/2021
12f
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/08/2021
mAb 4A8
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/12/2021
(Recombinant) IL-3
Potential treatment - pre-clinical evidence Experimental Other treatment Feb/18/2021
[SARSHRC-PEG4]2-chol
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/17/2021
MI-09
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/18/2021
MI-30
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/18/2021
WNbFc 36
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/23/2021
mAB 4-8
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/12/2021
GS‐441524
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/19/2021
WNbFc 15
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/23/2021
mAB 2-17
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/12/2021
CoV-X2
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/25/2021
WNbFc 7
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/23/2021
mAB 4-18
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/12/2021
ACE2‐TMPRSS2‐EVs
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/28/2020